There are a few stocks in my investment club's portfolio that seem, quite simply, to never catch a break. Of course, it begs the question of whether we should be investing in companies that need to catch a break.
Myriad Genetics (MYGN) is one of those investments. Our investment thesis in Myriad is based far more on our belief in the company's mission rather than in its performance or the actual financial data.
Myriad Genetics
Myriad Genetics provides molecular diagnostic tests. It focuses on "the role genes and proteins play in disease". It launched its